These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 24686006

  • 1. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
    Yang H, Xu W, Li Y, Lan P, Zhang J, Zhang Y, Zhang C.
    Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
    [Abstract] [Full Text] [Related]

  • 2. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
    Patra N, De U, Kim TH, Lee YJ, Ahn MY, Kim ND, Yoon JH, Choi WS, Moon HR, Lee BM, Kim HS.
    Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
    [Abstract] [Full Text] [Related]

  • 3. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
    Zhang Y, Fang H, Feng J, Jia Y, Wang X, Xu W.
    J Med Chem; 2011 Aug 11; 54(15):5532-9. PubMed ID: 21714538
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
    Xu Y, Voelter-Mahlknecht S, Mahlknecht U.
    Int J Mol Med; 2005 Jan 11; 15(1):169-72. PubMed ID: 15583844
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH, Zhang XB, Han XQ, Feng CR, Wang FS, Wang PG, Shen J, Shi YK.
    Oncol Rep; 2013 Jul 15; 30(1):499-505. PubMed ID: 23624828
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
    Sun DF, Zhang YJ, Tian XQ, Chen YX, Fang JY.
    Cell Biol Int; 2014 Jan 15; 38(1):50-63. PubMed ID: 24030871
    [Abstract] [Full Text] [Related]

  • 11. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.
    Cancer Res; 2003 May 01; 63(9):2118-26. PubMed ID: 12727828
    [Abstract] [Full Text] [Related]

  • 12. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
    Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH, Choi J, Ro S, Hyun YL, Lee JS, Kim CS.
    Anticancer Drugs; 2009 Oct 01; 20(9):815-21. PubMed ID: 19644355
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
    Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.
    PLoS One; 2013 Oct 01; 8(3):e58267. PubMed ID: 23469273
    [Abstract] [Full Text] [Related]

  • 14. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
    Yang L, Liang Q, Shen K, Ma L, An N, Deng W, Fei Z, Liu J.
    Biomed Pharmacother; 2015 Apr 01; 71():70-8. PubMed ID: 25960218
    [Abstract] [Full Text] [Related]

  • 15. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
    Zhang S, Huang WB, Wu L, Wang LY, Ye LB, Feng BH.
    Asian Pac J Cancer Prev; 2014 Apr 01; 15(10):4331-8. PubMed ID: 24935393
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X, Han H, Zou D, Zhou J, Zhou W.
    Oncotarget; 2017 Jan 10; 8(2):3364-3379. PubMed ID: 27926517
    [Abstract] [Full Text] [Related]

  • 18. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C, Jin JS, Chen BH, Chung HY, Chang CC, Hsu TY, Sun GH.
    Dis Esophagus; 2014 Jan 10; 27(7):693-702. PubMed ID: 24033428
    [Abstract] [Full Text] [Related]

  • 19. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP.
    Clin Cancer Res; 2007 Feb 01; 13(3):1045-52. PubMed ID: 17289901
    [Abstract] [Full Text] [Related]

  • 20. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
    Pai JT, Hsu CY, Hua KT, Yu SY, Huang CY, Chen CN, Liao CH, Weng MS.
    Molecules; 2015 May 04; 20(5):8000-19. PubMed ID: 25946558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.